Welcome to our dedicated page for Appili Ther news (Ticker: APLIF), a resource for investors and traders seeking the latest updates and insights on Appili Ther stock.
Appili Therapeutics Inc. (APLIF) is a biopharmaceutical leader focused on infectious disease treatments and biodefense solutions. This page provides investors and stakeholders with timely updates on the company’s clinical developments, regulatory milestones, and strategic initiatives.
Access the latest press releases, earnings reports, and partnership announcements in one centralized location. Stay informed about APLIF’s progress in advancing therapies for antimicrobial resistance, vaccine development, and public health threats.
Key updates include progress on genetically defined vaccines, FDA submissions, and collaborative research efforts. Bookmark this page for direct access to verified information that impacts investment decisions and industry trends.
Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) announced that Dr. Don Cilla, President and CEO, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 26, 2023, in Toronto. The presentation will highlight updates on Appili's pipeline, including ATI-1701, a tularemia vaccine funded by the U.S. Government, and ATI-1801, a treatment for cutaneous leishmaniasis. Both programs may qualify for FDA Priority Review Vouchers upon approval. The conference will include one-on-one meetings for investors. Appili Therapeutics focuses on developing novel anti-infectives to combat life-threatening infections.
FAQ
What is the current stock price of Appili Ther (APLIF)?
What is the market cap of Appili Ther (APLIF)?
